The Vitamin D Market was valued at USD 1.3 billion in 2022, is anticipated to reach USD 1.9 billion by 2027, registering a CAGR of 7.1% during the forecast period, primarily propelled by the rising demand for health and wellness products.
The comprehensive report, comprising 383 market data tables and 43 figures across 279 pages, with a detailed table of contents, is available.
The Vitamin D2 segment is expected to witness the highest growth rate during the forecast period, driven by its accessibility and utilization, especially in higher doses, for individuals with low vitamin D levels. This has prompted numerous manufacturers to shift their production focus from vitamin D3 to vitamin D2.
In terms of the form segment, the liquid type holds a significant share in the vitamin D market, owing to its easy absorption by the human body and its diverse applications in pharmaceuticals, food, dietary, and nutraceutical supplements.
Among the various applications, the feed & pet food segment claims the largest share in the vitamin D market due to the detrimental effects of vitamin D deficiency on poultry health, particularly in terms of growth and production.
The report also underscores the criticality of addressing vitamin D deficiency in children, as it can lead to diseases such as rickets, which impede proper bone development.
Asia Pacific emerges as the largest region for the vitamin D market in 2022, with a prevalent deficiency of vitamin D in South and Southeast Asia. This region's economic growth, significant feed production, and increasing manufacturing activities, supported by local governments, are key drivers of the market's expansion.
Moreover, the report features an analysis of the marketing and development strategies, alongside the product portfolios of leading companies. Profiles of prominent companies such as Zhejiang Garden Biochemical High-Tech Co. Ltd (China), Koninklijke DSM N.V. (Netherlands), Zhejiang Xinhecheng Co., Ltd. (China), Taizhou Haisheng Pharmaceutical Co., Ltd. (China), Xiamen Jindawei Vitamin Co., Ltd. (China), Fermenta Biotech Ltd. (India), Zhejiang Medicine Co., Ltd. (China), BASF (Germany), and Dishman Group (India) are included in the report.
